[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: NC6B42CB9CF8EN
DelveInsight

US$ 3,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Understanding

The DelveInsight Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology report gives a thorough understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) in the US, Europe, and Japan. The report covers the detailed information of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology scenario in seven major countries (US, EU5, and Japan).

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Perspective by DelveInsight

The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Detailed Epidemiology Segmentation

The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology covered in the report provides historical as well as forecasted Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
  • The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Report and Model provide an overview of the global trends of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
  • The report provides the segmentation of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology
Report Highlights
  • 11-year Forecast of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
  • Cases of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) by Mutation Types
  • Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Cases associated with Clinical Manifestations
KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)?
  • What are the key findings pertaining to the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)?
  • What are the currently available treatments of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)?
Reasons to buy

The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market
  • Quantify patient populations in the global Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) therapeutics in each of the markets covered
  • Understand the magnitude of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) population by its epidemiology
  • The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)

3. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Treatment and Management
6.2. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report


LIST OF TABLES

List of Table:
Table 1: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in 7MM (2019-2032)
Table 2: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in the United States (2019-2032)
Table 4: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Germany (2019-2032)
Table 6: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in France (2019-2032)
Table 8: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Italy (2019-2032)
Table 10: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Spain (2019-2032)
Table 12: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in the United Kingdom (2019-2032)
Table 14: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Japan (2019-2032)
Table 16: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Japan (2019-2032)


LIST OF FIGURES

List of Figures
Figure 1 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in 7MM (2019-2032)
Figure 2 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in the United States (2019-2032)
Figure 4 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Germany (2019-2032)
Figure 6 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in France (2019-2032)
Figure 8 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Italy (2019-2032)
Figure 10 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Spain (2019-2032)
Figure 12 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology in Japan (2019-2032)
Figure 16 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report

More Publications

Need Help?

Ask a Question

Market Reports

All Categories